1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. RETINAL DISORDER TREATMENT MARKET BY RETINAL CONDITION TYPE
5.1. Introduction
5.2. Macular Degeneration
5.3. Diabetic Retinopathy
5.4. Others
6. RETINAL DISORDER TREATMENT MARKET BY TREATMENT TYPE
6.1. Introduction
6.2. Pharmacological Therapies
6.3. Laser Therapies
6.4. Others
7. RETINAL DISORDER TREATMENT MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Others
8. RETINAL DISORDER TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Regeneron Pharmaceuticals Inc.
10.2. Roche Group
10.3. Novartis
10.4. Apellis Pharmaceuticals
10.5. Astellas Pharma
10.6. Belite Bio
10.7. Kodlak Sciences
10.8. JCyte Inc.
10.9. EyePoint Pharmaceuticals
10.10. Ocugen
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES